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background: Renal dysfunction (RD) is a potent prognostic indicator in patients with heart failure.  Notably, an elevated blood urea nitrogen to 
creatinine ratio (BUN/Creat) identifies a particularly high risk phenotype of RD, which may be due to the fact that elevated BUN/Creat is a surrogate 
for renal neurohormonal activation. If this hypothesis is true, a similar high risk phenotype of RD should be identifiable directly with plasma renin 
activity (PRA).
Methods: Patients with data on renal function available in the Studies Of Left Ventricular Dysfunction registry (n=5651) were studied with 
emphasis on the 701 neurohormonal substudy patients where PRA was determined.  RD was defined as an estimated glomerular filtration rate of 
<60 ml/min/1.73m2, an elevated BUN/Creat was defined as >20, and an elevated PRA was defined as a value above the median (1.3 ng/ml/hr). 
All models were adjusted for age, race, gender, hypertension, diabetes, heart rate and blood pressure.
results: In the overall population, RD was associated with significantly greater risk for mortality in patients with elevated BUN/Creat (HR=2.1, 95% 
CI 1.6-2.6, p<0.0001) compared to patients with a normal BUN/Creat (HR=1.3, 95% CI 1.1-1.6, p=0.003, p interaction=0.016).  Amongst patients 
with RD, PRA was significantly higher in those with an elevated BUN/Creat (10.4 ± 19.3 vs. 4.4 ± 8.1 ng/ml/hr, p=0.013). In the subgroup with PRA 
available, RD was not associated with increased mortality if PRA was below the median (HR=0.14, 95% CI 0.02-1.2, p=0.14).  However, in patients 
with a PRA above the median, RD was strongly associated with reduced survival (HR=2.7, 95% CI 1.2-5.9, p=0.017, p interaction=0.029).  The risk 
associated with RD tended to be the greatest in patients with both high PRA and high BUN/Creat (HR=3.5, 95% CI 1.1-11.3, p=0.035). 
conclusion:  The risk associated with RD in patients with HF appears to be largely restricted to patients with renal neurohormonal activation 
evidenced by an elevated PRA or BUN/Creat ratio.  Additional research is necessary to determine if renal function and outcomes can be improved 
with targeted therapy in these patients. 
